# VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders

> **NCT00304005** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vion Pharmaceuticals** · enrollment: 35 (estimated)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **DRUG:** laromustine

## Key facts

- **NCT ID:** NCT00304005
- **Lead sponsor:** Vion Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2005-10
- **Final completion:** 2008-08
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2013-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00304005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00304005, "VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00304005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*